Urokinase Plasminogen Activator System in Benign Prostatic Hyperplasia
1 other identifier
observational
30
1 country
1
Brief Summary
We hypothesize that the absolute or relative serum or urine levels of the urokinase plasminogen activator system, including uPA, uPAR and PAI-1,2 (inhibitors of the uPAR/uPA complex), are associated with inflammation in prostatic tissue.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Nov 2006
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2006
CompletedFirst Submitted
Initial submission to the registry
December 1, 2006
CompletedFirst Posted
Study publicly available on registry
December 5, 2006
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2008
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2012
CompletedNovember 6, 2013
November 1, 2013
1.3 years
December 1, 2006
November 5, 2013
Conditions
Keywords
Interventions
Eligibility Criteria
Men needing TURP
You may qualify if:
- scheduled for transurethral resection of the prostate
You may not qualify if:
- unable to give consent
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre for Advanced Urological Research
Kingston, Ontario, K7L 3J7, Canada
Related Publications (6)
Nickel JC. Prostatic inflammation in benign prostatic hyperplasia - the third component? Can J Urol. 1994 Jan;1(1):1-4.
PMID: 12834558BACKGROUNDNickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int. 1999 Dec;84(9):976-81. doi: 10.1046/j.1464-410x.1999.00352.x.
PMID: 10571623BACKGROUNDNickel JC, True LD, Krieger JN, Berger RE, Boag AH, Young ID. Consensus development of a histopathological classification system for chronic prostatic inflammation. BJU Int. 2001 Jun;87(9):797-805. doi: 10.1046/j.1464-410x.2001.02193.x.
PMID: 11412216BACKGROUNDMcCabe NP, Angwafo FF 3rd, Zaher A, Selman SH, Kouinche A, Jankun J. Expression of soluble urokinase plasminogen activator receptor may be related to outcome in prostate cancer patients. Oncol Rep. 2000 Jul-Aug;7(4):879-82. doi: 10.3892/or.7.4.879.
PMID: 10854562BACKGROUNDMcConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387-98. doi: 10.1056/NEJMoa030656.
PMID: 14681504BACKGROUNDThompson IN, Goodman PJ, Tangen CM, Lucia MS, Miller CJ, Ford LC, et al. The influence of finsteride in the development of prostate cancer. New England Journal of Medicine, 2003; 349:211-220.
BACKGROUND
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
J. Curtis Nickel, MD FRCSC
Queen's Universtiy
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
December 1, 2006
First Posted
December 5, 2006
Study Start
November 1, 2006
Primary Completion
February 1, 2008
Study Completion
January 1, 2012
Last Updated
November 6, 2013
Record last verified: 2013-11